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Taxonomy
Cryptococcosis, a systemic mycosis with a worldwide distribution, 
is caused by fungi within the pathogenic Cryptococcus 
neoformans-Cryptococcus gattii species complex. Until recently, 
this species complex simply included two species, namely C. 
neoformans (containing serotypes A [C. neoformans var. grubii], D 
[C. neoformans var. neoformans], and an AD hybrid) and C. gattii 
(containing serotypes B and C). In 2015, the current C. neoformans 
var. grubii and C. neoformans var. neoformans were proposed to 
be recognised as separate species, and five separate species 
were proposed within C. gattii, in addition to several hybrid 
species.1 While this revised nomenclature has taxonomic 
relevance, it is unlikely to filter down to the clinic, not least 
because the molecular tools to separate these cryptic species are 
rarely available at diagnostic laboratories.
Epidemiology
Largely fuelled by the AIDS pandemic, the global burden of 
cryptococcosis is enormous, with a recent estimate of 221 400 
(95% CI 180  640 to 267  600) cases per annum, 70% of which 
occur in sub-Saharan Africa (155  030 cases, 95% CI 126  950 to 
186  240).2 By country, Nigeria, India and South Africa are 
estimated to have the highest number of cases. Cryptococcus 
neoformans var. grubii [proposed name: C. neoformans] is the 
most common cause of meningitis among HIV-seropositive 
adults in southern and eastern Africa.3,4 Cryptococcosis rarely 
occurs in HIV-seronegative individuals (around 1% of cases in 
South Africa).5 Although most patients have a known risk factor, 
such as solid organ transplant or cell-mediated immunodeficiency, 
around 10%-40% are apparently immune-competent.6,7 Disease 
in immune-competent patients is commonly caused by C. gattii 
species-complex; is more likely to have extra-neural and extra-
pulmonary manifestations; and, is associated with a higher risk 
of mortality.6–9
Paediatric cryptococcosis is relatively less common than adult 
disease: 1 case per 100  000 people vs 19 cases per 100  000 
people in the general population.10
The case reported in this edition of the Journal is, therefore, 
unusual in several respects: disseminated disease (involving the 
lungs, blood, bone marrow, skin, meninges, urinary tract, liver 
and lymph nodes) caused by C. neoformans var. neoformans 
[proposed name: C. deneoformans], which occurred in a young 
child who was considered to be immune-competent.
Pathophysiology
Since Cryptococcus is a ubiquitous fungus, it is unsurprising that 
exposure, through inhalation of spores or desiccated yeast cells 
is likely to be almost universal during early childhood. Serological 
studies reveal that children acquire antibodies to C. neoformans 
from the age of two years,11 and that infection is usually 
asymptomatic in both immune-compromised and immune–
competent individuals.11–13
Following inhalation, Cryptococcus is thought to remain dormant 
in the body. Evidence of latency exists in the finding of continuous 
antibody production,11–14 molecular studies indicating that 
cryptococcosis presenting in Africans living in Europe was 
acquired many years earlier,15,16 and in autopsy studies from 
patients without a history of cryptococcal disease or exposure 
describing pulmonary granulomas containing C. neoformans.17,18 
The ability of the fungus to persist in humans without triggering 
a successful immune reaction has likely evolved due to its 
saprophytic nature (reviewed in 7–9). For example, C. neoformans 
is able to survive and replicate within macrophages in a similar 
way to which it exists as an intracellular parasite of amoebae in 
the environment.19,20 Furthermore, its polysaccharide capsule 
which protects it from harsh conditions, including UV light and 
extremes of temperature in the environment, exhibits 
antiphagocytic mechanisms, causing macrophage dysfunction 
and lysis, and allowing resistance to phagosomal digestion.21 
These, along with many other ‘ready-made’ virulence factors 
(production of melanin, degradative enzymes and an ability to 
grow at physiological temperatures),22 allow Cryptococcus to 
remain in dormant until host immune-compromise allows 
dissemination and disease, most commonly meningo-
encephalitis in HIV-infected individuals.
Although disease usually represents reactivation of latent 
infection in immune-compromised hosts, primary acquisition 
can also be associated with clinical symptoms.23 Acute infection 
may be more likely following exposure to a greater number of 
Cryptococcus cells.24 This may be the mechanism of cryptococcal 
disease described in this case.
The rare occurrence of cryptococcosis in apparently-
immunocompetent hosts highlights the multiplicity of innate 
and acquired immune factors, and complex immune interactions, 
required for successful defence against C. neoformans. Although 
CD4+ T-cell function is clearly of key importance (as demonstrated 
by the emergence of cryptococcosis alongside the HIV/AIDS 
epidemic), only 4%-11% of patients with CD4+ T-cell counts of 
less than 100 cells/μl in sub-Saharan Africa have cryptococcal 
antigen detectable in blood.25–34 This indicates that additional or 
underlying factors, in addition to CD4+ T-cell deficiency, may lead 
to increased susceptibility in a subset of individuals. A greater 
understanding of host immunity to cryptococcosis has been 
achieved though recent studies in animal models as well as 
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humans, both with and without immune-compromise. Research 
findings have established innate and acquired immune factors 
and genetic polymorphisms that influence an individual’s ability 
to resist or survive infection with C. neoformans (reviewed in 11,12). 
Cryptococcosis in patients in which no immune deficiency has 
been identified, such as in this case, may represent the existence 
of an underlying immunological or genetic predisposition.
Treatment
The Infectious Diseases Society of America (IDSA) recommends 
that apparently-immunocompetent patients (i.e. non-HIV and 
non-transplant recipients) with disseminated cryptococcosis are 
treated with high-dose amphotericin B (0.7–1.0 mg/kg per day) 
and flucytosine (100 mg/kg per day in 4 divided doses) for up to 
6  weeks followed by consolidation treatment with fluconazole 
(400  mg per day) for 8  weeks and maintenance low-dose 
fluconazole (200 mg [3 mg/kg] per day) for 6-12 months.35 This 
approach to treatment is based on two early clinical trials in a 
heterogeneous group of patients with meningitis who were 
neither HIV-infected nor transplant recipients: the first trial 
documented the superiority of a combination low-dose 
amphotericin B and high-dose flucytosine regimen vs low-dose 
amphotericin B alone; and, the second, the superiority of a 
6-week vs 4-week combination regimen.36,37 These trials were 
published prior to the availability of triazole agents and adoption 
of the standard 3-phase regimen with a high-dose amphotericin 
B and flucytosine backbone. Thus, the IDSA recommendations 
have been modified to include currently-accepted doses of 
amphotericin B deoxycholate and flucytosine and consolidation/
maintenance phases of treatment to reduce the risk of relapse. If 
flucytosine is not given or is unavailable, lengthening the 
duration of amphotericin B treatment by two weeks is 
recommended.35
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